ClinicalTrials.gg
TerminatedNCT07030868Updated Aug 31, 2026Results posted

A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

A Phase 2 interventional study of LY3549492 and Placebo in Obesity, Overweight and Type 2 Diabetes, sponsored by Eli Lilly and Company. Terminated at 42 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Why this study was terminated
Study terminated for strategic business reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 118 studies in Obesity by Eli Lilly and Company — 31 open to participants now, 55 under way, 30 of them phase 3. Obesity · Eli Lilly and Company.

Enrollment
116th of 117
1 · median 267
Started
2025
with 27 others
Phase 2
22 of 118
5 open now
Registered
84th of 118
by date

Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 116th largest by enrollment of the 117 interventional ones that give a count, is one of 28 that started in 2025, is one of 22 in phase 2, and was the 84th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

31 of the 118 studies in Obesity by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Obesity by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of treatment with LY3549492 compared to placebo in adult participants with obesity or who are overweight with type 2 diabetes.

Participation in the study will last about 11 months.

03

Conditions studied

  • Obesity
  • Overweight
  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

W8M-MC-GN02:

  • Assigned male at birth
  • Assigned female at birth, who are of non-
  • Have type 2 diabetes

W8M-MC-CWMM:

  • Have a ≥27 kilograms per square meter (kg/m²)
  • Have had a stable body weight for the 3 months prior to randomization (\<5% body weight gain and/or loss

Exclusion criteria

Exclusion Criteria:

W8M-MC-GN02:

  • Individuals who are of
  • Have a history of acute or chronic pancreatitis
  • Have any of the following cardiovascular conditions within 6 months prior to screening:

    • acute myocardial infarction
    • cerebrovascular accident (stroke)
    • unstable angina, or
    • hospitalization due to congestive heart failure.

W8M-MC-CWMM:

  • Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening
  • Have type 1 diabetes mellitus, latent diabetes in adults, or history of ketoacidosis or hyperosmolar coma
  • Have poorly controlled hypertension
  • Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease
  • Have a history of symptomatic gallbladder disease within the past 2 years
  • Have a lifetime history of suicide attempts
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    LY3549492 Low Dose

    Participants will receive LY3549492 orally

    Drug: LY3549492

  • Experimental
    LY3549492 High Dose with Fast Titration

    Participants will receive LY3549492 orally

    Drug: LY3549492

  • Experimental
    LY3549492 High Dose with Slow Titration

    Participants will receive LY3549492 orally

    Drug: LY3549492

  • Placebo comparator
    Placebo

    Participants will receive placebo orally

    Drug: Placebo

Interventions

  • Administered orally

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Body Weight

    Percent change from baseline in body weight at Week 32. Body weight was intended to be measured in kilograms, and percent change was to be calculated relative to baseline.

    Time frame: Baseline, Week 32

Secondary outcomes

  1. Change From Baseline in Body Weight

    Change from baseline in body weight at Week 32. Body weight was intended to be measured in kilograms, and absolute change from baseline was to be calculated.

    Time frame: Baseline, Week 32

  2. Percentage of Participants Who Achieve ≥5% Body Weight Reduction

    Percentage of participants who achieved at least 5% reduction in body weight from baseline to Week 32.

    Time frame: Baseline, Week 32

  3. Percentage of Participants Who Achieve ≥10% Body Weight Reduction

    Percentage of participants who achieved at least 10% reduction in body weight from baseline to Week 32.

    Time frame: Baseline, Week 32

  4. Change From Baseline in Hemoglobin A1c (HbA1c)

    Change from baseline in hemoglobin A1c (HbA1c) at Week 32. HbA1c was intended to be measured as a percentage and reflects average blood glucose levels over approximately 3 months.

    Time frame: Baseline, Week 32

  5. Pharmacokinetics (PK): Average Concentration of LY3549492

    Average plasma concentration of LY3549492. Pharmacokinetic samples were intended to be collected at multiple timepoints, including pre-dose and post-dose intervals, to evaluate the pharmacokinetic profile of LY3549492 over time.

    Time frame: Week 0 and Week 24 (6-18 hours post-dose); Weeks 3, 9, 15, and 18 (1-3 hours post-dose); Weeks 6 and 21 (3-6 hours post-dose); Week 12 (1-6 hours post-dose); and Weeks 30 and 32 (pre-dose).

07

Results

Posted Aug 31, 2026
Limitations and caveats
The study was terminated for strategic business reasons after the enrollment of 1 participant. The enrolled participant did not receive any study intervention and did not undergo any post-baseline assessments prior to study termination. Therefore, no outcome measures or safety data were collected, and no analyses could be performed.

Participant flow

The study was terminated for strategic business reasons after the enrollment of 1 participant. The enrolled participant did not receive any study intervention and did not undergo any post-baseline assessments prior to study termination. Therefore, no outcome measures or safety data were collected, and no analyses could be performed.

Participant flow — Overall Study
MilestoneLY3549492 or Placebo (Randomised, Not Treated)
Started1
Received at least one dose of study drug0
Completed0
Not completed1

Outcome measures

PrimaryPercent Change From Baseline in Body Weight

Percent change from baseline in body weight at Week 32. Body weight was intended to be measured in kilograms, and percent change was to be calculated relative to baseline.

Time frame:
Baseline, Week 32

No measurements were reported for this outcome.

SecondaryChange From Baseline in Body Weight

Change from baseline in body weight at Week 32. Body weight was intended to be measured in kilograms, and absolute change from baseline was to be calculated.

Time frame:
Baseline, Week 32

No measurements were reported for this outcome.

SecondaryPercentage of Participants Who Achieve ≥5% Body Weight Reduction

Percentage of participants who achieved at least 5% reduction in body weight from baseline to Week 32.

Time frame:
Baseline, Week 32

No measurements were reported for this outcome.

SecondaryPercentage of Participants Who Achieve ≥10% Body Weight Reduction

Percentage of participants who achieved at least 10% reduction in body weight from baseline to Week 32.

Time frame:
Baseline, Week 32

No measurements were reported for this outcome.

SecondaryChange From Baseline in Hemoglobin A1c (HbA1c)

Change from baseline in hemoglobin A1c (HbA1c) at Week 32. HbA1c was intended to be measured as a percentage and reflects average blood glucose levels over approximately 3 months.

Time frame:
Baseline, Week 32

No measurements were reported for this outcome.

SecondaryPharmacokinetics (PK): Average Concentration of LY3549492

Average plasma concentration of LY3549492. Pharmacokinetic samples were intended to be collected at multiple timepoints, including pre-dose and post-dose intervals, to evaluate the pharmacokinetic profile of LY3549492 over time.

Time frame:
Week 0 and Week 24 (6-18 hours post-dose); Weeks 3, 9, 15, and 18 (1-3 hours post-dose); Weeks 6 and 21 (3-6 hours post-dose); Week 12 (1-6 hours post-dose); and Weeks 30 and 32 (pre-dose).

No measurements were reported for this outcome.

Adverse events

Collected over All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events data were not collected/assessed in this study. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY3549492 or Placebo (Randomised, Not Treated)———

Baseline characteristics

All enrolled participants.

Age, Categorical
Age, Categorical(Participants)LY3549492 or Placebo (Randomised, Not Treated)
<=18 years0
Between 18 and 65 years1
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)LY3549492 or Placebo (Randomised, Not Treated)
Female0
Male1
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LY3549492 or Placebo (Randomised, Not Treated)
Hispanic or Latino0
Not Hispanic or Latino1
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LY3549492 or Placebo (Randomised, Not Treated)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White1
More than one race0
Unknown or Not Reported0
08

Study locations

42 sites
  • HOPE Research Institute
    Phoenix, Arizona 85032, United States
  • Headlands Research - Scottsdale
    Scottsdale, Arizona 85260, United States
  • NorCal Medical Research, Inc
    Greenbrae, California 94904, United States
  • Velocity Clinical Research, Huntington Park
    Huntington Park, California 90255, United States
  • Peninsula Research Associates
    Rolling Hills Estates, California 90274, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Stamford Therapeutics Consortium
    Stamford, Connecticut 06905, United States
  • Northeast Research Institute (NERI)
    Fleming Island, Florida 32003, United States
  • Indago Research & Health Center, Inc
    Hialeah, Florida 33012, United States
  • New Horizon Research Center
    Miami, Florida 33165, United States
  • Suncoast Clinical Research, Inc.
    New Port Richey, Florida 34652, United States
  • Charter Research - Winter Park
    Orlando, Florida 32803, United States
  • Charter Research - Lady Lake
    The Villages, Florida 32162, United States
  • Medical Research Partners
    Ammon, Idaho 83406, United States
  • Great Lakes Clinical Trials - Ravenswood
    Chicago, Illinois 60640, United States
  • Iowa Diabetes and Endocrinology Research Center
    West Des Moines, Iowa 50266, United States
  • Cotton O'Neil Diabetes & Endocrinology
    Topeka, Kansas 66606, United States
  • Knownwell
    Needham, Massachusetts 02492, United States
  • Lucida Clinical Trials
    New Bedford, Massachusetts 02740, United States
  • Headlands Research - Detroit
    Southfield, Michigan 48034, United States
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
    Troy, Michigan 48098, United States
  • Clinvest Headlands Llc
    Springfield, Missouri 65807, United States
  • Las Vegas Medical Research
    Las Vegas, Nevada 89128, United States
  • Velocity Clinical Research, Syracuse
    East Syracuse, New York 13057, United States
  • Rochester Clinical Research, LLC
    Rochester, New York 14609, United States
  • Monroe Biomedical Research
    Monroe, North Carolina 28112, United States
  • Lucas Research, Inc
    Morehead City, North Carolina 28557, United States
  • Lucas Research, Inc.
    New Bern, North Carolina 28562, United States
  • Quality Medical Research
    Nashville, Tennessee 37211, United States
  • IMA Clinical Research Austin
    Austin, Texas 78745, United States
  • Velocity Clinical Research, Dallas
    Dallas, Texas 75230, United States
  • FutureSearch Trials of Dallas
    Dallas, Texas 75251, United States
  • PlanIt Research, PLLC
    Houston, Texas 77079, United States
  • Tekton Research - Fredericksburg Road
    San Antonio, Texas 78229, United States
  • Endeavor Clinical Trials
    San Antonio, Texas 78240, United States
  • Texas Valley Clinical Research
    Weslaco, Texas 78596, United States
  • Spectrum Medical, Inc.
    Danville, Virginia 24541, United States
  • Central Washington Health Services Association d/b/a Confluence Health
    Wenatchee, Washington 98801, United States
  • Centro Médico Viamonte
    Buenos Aires, Buenos Aires F.D. C1120AAC, Argentina
  • Consultorio de Investigación Clínica EMO SRL
    Buenos Aires, Buenos Aires F.D. C1405BUB, Argentina
  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
    Buenos Aires, Buenos Aires F.D. C1425AGC, Argentina
  • Centro de Investigaciones Metabólicas (CINME)
    Buenos Aires, C1056ABI, Argentina
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2025 to primary completion in Jul 2025, 1 month.

Results were first posted in Aug 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2025
First posted
Jun 22, 2025
StartActual
Jun 19, 2025
Primary completionActual
Jul 29, 2025
CompletionActual
Jul 29, 2025
Results first posted
Aug 31, 2026
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07030868
Responsible party
Sponsor
First posted
Jun 22, 2025
Start date
Jun 19, 2025
Primary completion
Jul 29, 2025
Completion
Jul 29, 2025
Results posted
Aug 31, 2026
Last update
Aug 31, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naperiglipron

Start the discussion